Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy

Bulletin of Mathematical Biology

Volumn 71, Issue 3, 2009, Pages 648-680

  Rida, Wasima ^a   Sandberg, Sonja ^b  

^a AMERICAN UNIVERSITY   (United States)

^b FRAMINGHAM STATE UNIVERSITY   (United States)

Author keywords

AIDS; Basic reproduction number; Epidemic models; HAART; HIV; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; COMPUTER SIMULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; VIROLOGY;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASIC REPRODUCTION NUMBER; COMPUTER SIMULATION; HIV; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MODELS, IMMUNOLOGICAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62149103367     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-008-9375-5     Document Type: Article

References (60)

1. L. Abu-Raddad M. Boily S. Self I. Longini Jr. 2007 Analytic insights into the population level impact of imperfect prophylactic HIV vaccines J. Acquir. Immune Defic. Syndr. 45 4 454 467
2. R. Anderson M. Hanson 2005 Potential public health impact of imperfect HIV type 1 vaccines J. Infect. Dis. 191 S1 S85 S96
3. R. Anderson J. Swinton G. Garnett 1995 Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection Proc. R. Soc. Lond. Ser. B - Biol. Sci. 261 1361 147 151
4. J. Arino K. Cooke P. van den Driessche J. Velasco-Hernandez 2004 An epidemiology model that includes a leaky vaccine with a general waning function Discrete Contin. Dyn. Syst. Ser. B 4 2 479 495
5. A. Babiker S. Darby D. De Angelis D. Ewart K. Porter 2000 Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative reanalysis Lancet 355 1131 1137
6. R. Baggaley G. Garnett N. Ferguson 2006 Modelling the impact of antiretroviral use in resource-poor settings PLoS Med. 3 4 e124
7. Bartlett, J., Lane, H., Anderson, J., Baker, A., Bozzette, S., Carpenter, C., Delaney, M., El-Sadr, L., Fletcher, C. et al., 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS-Office of AIDS Research Advisory Council.
8. S. Blower E. Bodine K. Grovit-Ferbas 2005 Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of subtypes Curr. Drug Targets-Infect. Disord. 5 179 192
9. S. Blythe C. Castillo-Chavez 1989 Like-with-like preference and sexual mixing models Math. Biosci. 96 2 221 238
10. C. Burr 1998 Of AIDS and altruism US News World Rep. 124 13 60 61
11. J. Cohen 2007 AIDS research: promising AIDS vaccine's failure leaves field reeling Science 318 5847 28 29
12. M. Davenport R. Ribeiro D. Chao A. Perelson 2004 Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus J. Virol. 78 20 11,340 11,351
13. S. Deeks 2003 Treatment of antiretroviral-drug-resistant HIV-1 infection Lancet 362 9400 2002 2011
14. S. Del Valle A. Morales Evangelista M. Cristina Velasco C. Kribs-Zaleta S. Hsu Schmitz 2004 Effects of education, vaccination and treatment on HIV transmission in homosexuals with genetic heterogeneity Math. Biosci. 187 2 111 133
15. 0 in heterogeneous populations J. Math. Biol. 28 365 382
16. K. Dietz 1993 The estimation of the basic reproduction number for infectious diseases Stat. Methods Med. Res. 2 1 23 24
17. J. Dushoff 1996 Incorporating immunological ideas in epidemiological models J. Theor. Biol. 180 3 181 187
18. E. Elbasha A. Gumel 2006 Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits Bull. Math. Biol. 68 3 577 614
19. P. Gilbert V. DeGruttola M. Hudgens S. Self S. Hammer L. Corey 2003 What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials J. Infect. Dis. 188 2 179 193
20. F. Goebel 2005 Immune reconstitution inflammatory syndrome (IRIS) another new disease entity following treatment initiation of HIV infection Infection 33 1 43 45
21. R. Gray M. Wawer R. Brookmeyer N. Sewankambo D. Serwadda F. Wabwire-Mangen T. Lutalo X. Li T. vanCott T. Quinn 2001 Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda Lancet 357 9263 1149 1153
22. A. Gumel C. McCluskey P. van den Driessche 2006 Mathematical study of a staged-progression HIV model with imperfect vaccine Bull. Math. Biol. 68 8 2105 2128
23. D. Hoyert H. Kung B. Smith 2005 Deaths: preliminary data for 2003 Nat. Vital Stat. Rep. 53 15 1 48
24. S. Hsu Schmitz 2000 Effects of treatment or/and vaccination on HIV transmission in homosexuals with genetic heterogeneity Math. Biosci. 167 1 1 18
25. W. Huang K. Cooke C. Castillo-Chavez 1992 Stability and bifurcation for a multiple-group model for the dynamics of HIV/AIDS transmission SIAM J. Appl. Math. 52 835 854
26. J. Hyman J. Li E. Stanley 1999 The differential infectivity and staged progression models for the transmission of HIV Math. Biosci. 155 2 77 109
27. IAVI, 2007. International AIDS Vaccine Initiative vaccine database. http://www.iavi.org.
28. L. Jacobson J. Phair T. Yamashita 2004 Update on the virologic and immunologic response to highly active antiretroviral therapy Curr. Infect. Dis. Rep. 6 4 325 332
29. J. Jacquez C. Simon J. Koopman L. Sattenspiel T. Perry 1988 Modeling and analyzing HIV transmission: the effect of contact patterns Math. Biosci. 92 2 119 199
30. M. Katz S. Schwarcz T. Kellogg J. Klausner J. Dilley S. Gibson W. McFarland 2002 Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco Am. J. Public Heath 92 388 394
31. M. Kgosimore E. Lungu 2004 The effects of vaccination and treatment on the spread of HIV/AIDS J. Biol. Syst. 12 4 399 417
32. J. King Jr. A. Justice M. Roberts C. Chang J. Fusco 2003 Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era Med. Decis. Mak. 23 1 9 20
33. M. Kretzschmar K. Dietz 1998 The effect of pair formation and variable infectivity on the spread of an infection without recovery Math. Biosci. 148 1 83 113
34. C. Kribs-Zaleta J. Velasco-Hernández 2000 A simple vaccination model with multiple endemic states Math. Biosci. 164 2 183 201
35. X. Lin H. Hethcote P. Van den Driessche 1993 An epidemiological model for HIV/AIDS with proportional recruitment Math. Biosci. 118 2 181 95
36. J. Louie L. Hsu D. Osmond M. Katz S. Schwarcz 2002 Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998 J. Infect. Dis. 186 7 1023 1027
37. R. Lyles A. Munoz T. Yamashita H. Bazmi R. Detels C. Rinaldo J. Margolick J. Phair J. Mellors 2000 Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men J. Infect. Dis. 181 3 872 880
38. Macey, R., Oster, G., 2000. Berkeley madonna. Version 801.
39. E. Massad F. Coutinho M. Burattini L. Lopez C. Struchiner 2001 Modeling the impact of imperfect HIV vaccines on the incidence of the infection Math. Comput. Model. 34 3-4 345 351
40. C. McCluskey 2003 A model of HIV/AIDS with staged progression and amelioration Math. Biosci. 181 1 1 16
41. J. Montaner R. Hogg E. Wood T. Kerr M. Tyndall A. Levy P. Harrigan 2006 The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic Lancet 368 9534 531 536
42. M. Morris M. Kretzschmar 1997 Concurrent partnerships and the spread of HIV AIDS 11 5 641 648
43. A. Paltiel M. Weinstein A. Kimmel G. Seage III E. Losina H. Zhang K. Freedberg R. Walensky 2005 Expanded screening for HIV in the United States-an analysis of cost-effectiveness N. Engl. J. Med. 352 6 586 595
44. C. Pilcher H. Tien J. Eron Jr. P. Vernazza S. Leu P. Stewart L. Goh M. Cohen 2004 Brief but efficient: acute HIV infection and the sexual transmission of HIV J. Infect. Dis. 189 10 1785 1792
45. P. Pitisuttithum P. Gilbert M. Gurwith W. Heyward M. Martin F. van Griensven D. Hu J. Tappero K. Choopanya 2006 Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J. Infect. Dis. 194 12 1661 1671
46. T. Porco J. Martin K. Page-Shafer A. Cheng E. Charlebois R. Grant D. Osmond 2004 Decline in HIV infectivity following the introduction of highly active antiretroviral therapy AIDS 18 1 81 88
47. T. Quinn M. Wawer N. Sewankambo D. Serwadda C. Li F. Wabwire-Mangen M. Meehan T. Lutalo R. Gray 2000 Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai project study group N. Engl. J. Med. 342 13 921 929
48. S. Rerks-Ngarm A. Brown C. Khamboonruang P. Thongcharoen P. Kunasol 2006 HIV/AIDS preventive vaccine'prime-boost'phase III trial: foundations and initial lessons learned from Thailand AIDS 20 11 1471 1479
49. rgp120 HIV Vaccine Study Group 2005 Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J. Infect. Dis. 191 654 665
50. M. Safan H. Heesterbeek K. Dietz 2006 The minimum effort required to eradicate infections in models with backward bifurcation J. Math. Biol. 53 4 703 718
51. G. Sanders A. Bayoumi V. Sundaram S. Bilir C. Neukermans C. Rydzak L. Douglass L. Lazzeroni M. Holodniy D. Owens 2005 Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy N. Engl. J. Med. 352 6 570 585
52. F. Sifakis C. Flynn L. Metsch M. LaLota C. Murrill B. Koblin T. Bingham W. McFarland H. Raymond S. Behel 2005 HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men-five US cities, June 2004-April 2005 Morb. Mortal. Wkly. Rep. 54 24 597 601
53. P. Smith L. Rodrigues P. Fine 1984 Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies Int. J. Epidemiol. 13 1 87 93
54. R. Smith S. Blower 2004 Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect. Dis. 4 10 636 639
55. R. Thiebaut H. Jacqmin-Gadda A. Babiker D. Commenges the Cascade Collaboration 2005 Joint modelling of bivariate longitudinal data with informative dropout and left censoring, with application to the evolution of CD4+ cell counts and HIV RNA viral load in response to treatment of HIV infection Stat. Med. 24 65 82
56. G. Toth 2000 Survival after introduction of HAART in people with known duration of HIV-1 infection Lancet 355 1158 1159
57. UNAIDS, 2007. 2007 AIDS epidemic update. http://www.unaids.org/en/HIV- data/2007EpiUpdate/default.asp.
58. P. van den Driessche J. Watmough 2002 Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission Math. Biosci. 180 1-2 29 48
59. E. Vittinghoff J. Douglas F. Judson D. McKirnan K. MacQueen S. Buchbinder 1999 Per-contact risk of human immunodeficiency virus transmission between male sexual partners Am. J. Epidemiol. 150 3 306 311
60. D. Watkins D. Burton E. Kallas J. Moore W. Koff 2008 Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans Nat. Med. 14 6 617 621